ALVOHealthcare · Drug Manufacturers - Specialty & GenericThe 7 Wall Street analysts covering Alvotech hold a median 12-month price target of $8 — +68.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 27 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Alvotech on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (96): The business earns solid, repeatable profits on what it owns.
Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ALVO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +68.4% from it.
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Sept 2026 | Barclays | Upgrade | Overweight | $4.00 → $8.00 |
| 24 Aug 2026 | B of A Securities | Initiates | Buy | — |
| 24 Aug 2026 | B of A Securities | Initiates | Buy | $7.00 |
| 14 Aug 2026 | Evercore ISI Group | Initiates | Outperform | — |
| 14 Aug 2026 | Evercore ISI Group | Initiates | Outperform | — |
| 24 Mar 2026 | Barclays | Maintains | Underweight | — |
| 24 Mar 2026 | Barclays | Maintains | Underweight | $5.00 → $4.00 |
| 24 Mar 2026 | UBS | Maintains | Buy | $10 → $6.00 |
| 24 Mar 2026 | UBS | Maintains | Buy | — |
| 9 Dec 2025 | Barclays | Initiates | Underweight | — |
| 18 Nov 2025 | UBS | Maintains | Buy | — |
| 4 Nov 2025 | Deutsche Bank | Downgrade | Hold | — |
| 14 Oct 2025 | Morgan Stanley | Upgrade | Overweight | — |
| 23 Sept 2025 | Deutsche Bank | Upgrade | Buy | — |
| 18 July 2025 | UBS | Maintains | Buy | — |
| 14 Feb 2025 | UBS | Initiates | Buy | — |
| 25 July 2024 | Barclays | Maintains | Overweight | — |
| 24 May 2024 | Barclays | Maintains | Overweight | — |
| 22 Mar 2024 | Barclays | Maintains | Overweight | — |
| 29 Jan 2024 | Barclays | Upgrade | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ALVO appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Alvotech returned −41.6% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 18% of US stocks
Cheaper than 35% of US stocks
Cheaper than 97% of US stocks
Cheaper than 6% of US stocks
Higher than 7% of US stocks
Higher than 13% of US stocks
Higher than 63% of US stocks
Higher than 24% of US stocks
Higher than 12% of US stocks
Higher than 36% of US stocks
Higher than 60% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alvotech has a market value of $1.6B and an enterprise value of $3.0B.
Revenue in the twelve months to 30 June 2026: $492.0M. The latest quarter shrank 38.9% year on year.
Net income over the same four quarters: −$179.6M, a −36.5% net margin.
Free cash flow in the twelve months to 30 June 2026: −$333.8M.
Trailing P/E: 42.4×; forward P/E: 20.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Alvotech employs 1,279 people — $385K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alvotech — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Alvotech announced it will release financial results for the nine-month period and third quarter ended September 30, 2026, on November 11, 2026, after the U.S. market close.
Why it matters — ALVO watchers may note the scheduled date for the company’s upcoming financial results announcement.
Alvotech (ALVO) was added to the Zacks Rank #5 (Strong Sell) list on October 21, 2026, alongside CSIQ and AESI.
Why it matters — The listing signals that Zacks classified ALVO among its Strong Sell-ranked stocks on that date.
Alvotech received FDA approval for a new SIMLANDI® manufacturing process that more than doubles output per batch. The enhanced process increases productivity and frees capacity across its biosimilars portfolio.
Why it matters — The approval may help Alvotech expand manufacturing capacity to support growing demand across its biosimilars portfolio.
Alvotech and Advanz Pharma announced that AVT29 has been submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg). They describe it as the first known worldwide regulatory submission for a proposed biosimilar to Eylea® 8 mg.
Why it matters — The submission is a regulatory milestone for Alvotech’s proposed biosimilar to Eylea® 8 mg.
Alvotech and LOTTE Biologics announced a long-term manufacturing partnership under which LOTTE will produce drug substance for multiple antibody biosimilar products at its Syracuse, New York facility for global supply. The companies said the collaboration could expand over time.
Why it matters — The agreement is intended to increase Alvotech’s global manufacturing capacity and support growth in demand for its biosimilar products.
The 7 Wall Street analysts covering Alvotech have a median 12-month price target of $8, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Alvotech, 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alvotech 32 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Alvotech ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +68.4% from the last close, and Ticker Nerd's factor model ranks Alvotech 32 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Alvotech publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALVO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.
Alvotech returned -41.6% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Alvotech SA is a biotechnology company focused on the development and manufacture of biosimilar medicines. Alvotech SA specializes in creating high-quality, cost-competitive alternatives to established biologic therapies, with products and candidates spanning autoimmune diseases, eye disorders, osteoporosis, respiratory disease, oncology, and other therapeutic areas.
The most recent item we track (GlobeNewsWire, 28 Oct 2026): "Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026". Alvotech announced it will release financial results for the nine-month period and third quarter ended September 30, 2026, on November 11, 2026, after the U.S. market close.
Alvotech SA is a biotechnology company focused on the development and manufacture of biosimilar medicines. Alvotech SA specializes in creating high-quality, cost-competitive alternatives to established biologic therapies, with products and candidates spanning autoimmune diseases, eye disorders, osteoporosis, respiratory disease, oncology, and other therapeutic areas. The company operates a vertically integrated model that covers the biosimilar value chain from cell line development and research to commercial manufacturing. Its portfolio includes monoclonal antibodies and fusion proteins designed to support treatment access across global patient markets. Alvotech SA works through strategic partnerships to extend commercialization and distribution reach across North America, Europe, Asia, and other international markets. Headquartered in Luxembourg, Alvotech SA plays a role in expanding access to biosimilar medicines within the global biopharmaceutical sector.
CEO Mr. Robert Wessman · 1,279 employees · Luxembourg · https://www.alvotech.com
